Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center

Thomas K. Lee, Alcides Chaux, Sarah Karram, Hiroshi Miyamoto, Jeremy S. Miller, Daniel A. Fajardo, Jonathan I. Epstein, George J. Netto

Research output: Contribution to journalArticle

Abstract

Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. For this purpose, 34 primary in-house cases diagnosed and treated between 1998 and 2008 were identified from our medical records. Upon review, 3 cases were upgraded to noninvasive low-grade urothelial carcinomas and excluded from further evaluation. During follow-up (range, 3-108 months; mean, 42 months), 13 patients developed recurrences; and 9 patients progressed to a noninvasive higher grade lesion (8 to low-grade and 1 to high-grade urothelial carcinomas). None of our patients developed stage progression (>pTa) or died of bladder cancer. Size of the primary tumor was associated with the risk of recurrence (P = .043), whereas the number of episodes of recurrence was associated with the likelihood of grade progression (P = .034). In conclusion, recurrences were observed in 42% of all our patients, with a grade progression rate of 29%. None of our patients developed invasive carcinoma or died as a consequence of their disease. Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted.

LanguageEnglish (US)
JournalHuman Pathology
DOIs
StateAccepted/In press - 1800

Fingerprint

Urinary Bladder
Recurrence
Neoplasms
Carcinoma
Urinary Bladder Neoplasms
Medical Records

Keywords

  • Noninvasive urothelial carcinoma
  • Papillary urothelial neoplasm of low malignant potential
  • Prognosis
  • Progression rate
  • PUNLMP
  • Recurrence rate

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Papillary urothelial neoplasm of low malignant potential of the urinary bladder : clinicopathologic and outcome analysis from a single academic center. / Lee, Thomas K.; Chaux, Alcides; Karram, Sarah; Miyamoto, Hiroshi; Miller, Jeremy S.; Fajardo, Daniel A.; Epstein, Jonathan I.; Netto, George J.

In: Human Pathology, 1800.

Research output: Contribution to journalArticle

Lee, Thomas K. ; Chaux, Alcides ; Karram, Sarah ; Miyamoto, Hiroshi ; Miller, Jeremy S. ; Fajardo, Daniel A. ; Epstein, Jonathan I. ; Netto, George J./ Papillary urothelial neoplasm of low malignant potential of the urinary bladder : clinicopathologic and outcome analysis from a single academic center. In: Human Pathology. 1800
@article{0bb07d795008465f9df987628fd39606,
title = "Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center",
abstract = "Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. For this purpose, 34 primary in-house cases diagnosed and treated between 1998 and 2008 were identified from our medical records. Upon review, 3 cases were upgraded to noninvasive low-grade urothelial carcinomas and excluded from further evaluation. During follow-up (range, 3-108 months; mean, 42 months), 13 patients developed recurrences; and 9 patients progressed to a noninvasive higher grade lesion (8 to low-grade and 1 to high-grade urothelial carcinomas). None of our patients developed stage progression (>pTa) or died of bladder cancer. Size of the primary tumor was associated with the risk of recurrence (P = .043), whereas the number of episodes of recurrence was associated with the likelihood of grade progression (P = .034). In conclusion, recurrences were observed in 42{\%} of all our patients, with a grade progression rate of 29{\%}. None of our patients developed invasive carcinoma or died as a consequence of their disease. Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted.",
keywords = "Noninvasive urothelial carcinoma, Papillary urothelial neoplasm of low malignant potential, Prognosis, Progression rate, PUNLMP, Recurrence rate",
author = "Lee, {Thomas K.} and Alcides Chaux and Sarah Karram and Hiroshi Miyamoto and Miller, {Jeremy S.} and Fajardo, {Daniel A.} and Epstein, {Jonathan I.} and Netto, {George J.}",
year = "1800",
doi = "10.1016/j.humpath.2011.03.006",
language = "English (US)",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Papillary urothelial neoplasm of low malignant potential of the urinary bladder

T2 - Human Pathology

AU - Lee,Thomas K.

AU - Chaux,Alcides

AU - Karram,Sarah

AU - Miyamoto,Hiroshi

AU - Miller,Jeremy S.

AU - Fajardo,Daniel A.

AU - Epstein,Jonathan I.

AU - Netto,George J.

PY - 1800

Y1 - 1800

N2 - Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. For this purpose, 34 primary in-house cases diagnosed and treated between 1998 and 2008 were identified from our medical records. Upon review, 3 cases were upgraded to noninvasive low-grade urothelial carcinomas and excluded from further evaluation. During follow-up (range, 3-108 months; mean, 42 months), 13 patients developed recurrences; and 9 patients progressed to a noninvasive higher grade lesion (8 to low-grade and 1 to high-grade urothelial carcinomas). None of our patients developed stage progression (>pTa) or died of bladder cancer. Size of the primary tumor was associated with the risk of recurrence (P = .043), whereas the number of episodes of recurrence was associated with the likelihood of grade progression (P = .034). In conclusion, recurrences were observed in 42% of all our patients, with a grade progression rate of 29%. None of our patients developed invasive carcinoma or died as a consequence of their disease. Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted.

AB - Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. For this purpose, 34 primary in-house cases diagnosed and treated between 1998 and 2008 were identified from our medical records. Upon review, 3 cases were upgraded to noninvasive low-grade urothelial carcinomas and excluded from further evaluation. During follow-up (range, 3-108 months; mean, 42 months), 13 patients developed recurrences; and 9 patients progressed to a noninvasive higher grade lesion (8 to low-grade and 1 to high-grade urothelial carcinomas). None of our patients developed stage progression (>pTa) or died of bladder cancer. Size of the primary tumor was associated with the risk of recurrence (P = .043), whereas the number of episodes of recurrence was associated with the likelihood of grade progression (P = .034). In conclusion, recurrences were observed in 42% of all our patients, with a grade progression rate of 29%. None of our patients developed invasive carcinoma or died as a consequence of their disease. Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted.

KW - Noninvasive urothelial carcinoma

KW - Papillary urothelial neoplasm of low malignant potential

KW - Prognosis

KW - Progression rate

KW - PUNLMP

KW - Recurrence rate

UR - http://www.scopus.com/inward/record.url?scp=79960328111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960328111&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2011.03.006

DO - 10.1016/j.humpath.2011.03.006

M3 - Article

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -